Multiple independent reports have demonstrated pericyte loss in both the hippocampus and cortex in human Alzheimer's disease (AD). The differentiation and recruitment of pericytes are the essential steps in vasculature development. However, the role of amyloid beta (Aβ) in pericyte differentiation has not yet been fully elucidated. In this study, we investigated the interaction between Aβ and differentiation of mesenchymal stem cells (MSCs) toward pericytes in culture. Our results showed that mice overexpressing Aβ-precursor protein (APP/PS1) exhibited the loss of pericytes compared with the control group mice, evidenced by the lack of desmin expression in the cortex of 12-month-old mice. Interestingly, we further found that both Aβ 40 and Aβ 42 inhibited the expressions of pericyte markers (α-SMA, desmin, and PDGFRβ) in cultured MSCs which can be differentiated into mature pericytes. Mechanistically, the inhibitory effects of Aβs on MSC-pericyte transition is mediated by the activation of the ERK1/2 MAPK signal pathway. These new insights into the roles of Aβ in pericyte differentiation may help to develop more effective strategies for the treatment of AD.
Introduction
Pericytes are commonly categorized as a subtype of perivascular cells which embedded within the neurovascular unit between endothelial cells of brain capillaries, astrocytes, and neurons, a site of the bloodbrain barrier (BBB) in vivo [1] [2] [3] . A previous study highlighted the importance of this barrier [4] which isolates the brain from the whole body and restricts exchanges between the brain and the peripheral compartments in Alzheimer's disease (AD). Sengillo et al. [5] have shown that pericytes regulate the key neurovascular functions, including BBB formation and maintenance, vascular stability and clearance of toxic cellular by-products necessary for normal functioning of the central nervous system. AD is a neurodegenerative disorder characterized by abnormal elevation of amyloid-β (Aβ) peptide, tau pathology, neuronal loss, and vascular dysfunction [6, 7] . In murine transgenic models, it has been shown that pericytes play a critical role in maintaining the BBB integrity, and that loss of pericytes can lead to a long-term BBB breakdown and small vessel disease contributing to neurodegenerative changes [8] [9] [10] . Multiple independent reports have demonstrated that pericyte, a major cerebrovasculature component, is degenerated and reduced in both the hippocampus and cortex in human AD [8, 10, 11] . However, the reasons and mechanisms leading to pericyte degeneration and loss remain unknown.
It is widely recognized that pericytes have mesenchymal or hematopoietic origin and that they are recruited to endothelial tubes [12] [13] [14] [15] . However, the role of Aβ in the differentiation of mesenchymal stem cells (MSCs) to pericytes is still to be explored. Therefore, we are interested in exploring whether the accumulation of Aβ has the ability to inhibit the transition of mesenchymal precursor cells to pericytes and to influence the brain vessel maintenance. We also determined whether the accumulation of Aβ in brain is responsible for the loss of pericytes in human AD. Our results demonstrated that Aβ is capable of weakening the differentiation of MSCs into pericytes, and then recruits them to bind with endothelial cells differentially. This study also revealed that MAPK signal may be the responsible molecular mechanism for the inhibitory effect of Aβs on pericyte differentiation.
Materials and Methods

Cells and reagents
Human umbilical cord-derived MSCs and MSC growth medium were obtained from Union Stemcell & Gene Engineering Co. Ltd (Tianjin, China). Cells were maintained in a humid atmosphere of 5% CO 2 at 37°C. Cells at passage 4 were used for further studies.
Antibody against desmin was from Santa Cruz Biotech (Santa Cruz, USA). Antibody against α-SMA was from Abcam (Cambridge, USA). Anti-CD31 antibody, PE mouse antihuman CD73 antibody, and PE mouse antihuman CD105 antibody were purchased from BD Biosciences (San Jose, USA). Antibodies against phospho-ERK1/2, ERK1/2, and MEK inhibitor PD98059 were from Cell Signaling Technology (Beverly, USA). Purified anti-β-Amyloid (6E10) was from Biolegend (San Diego, USA). Cell counting kit-8 assay (CCK-8) was purchased from Dojindo Laboratories (Kumamoto, Japan).
Transgenic mice
All animal experiments were approved and performed in accordance with institutional guidelines of Tianjin Medical University. APP/PS1 transgenic [B6C3-Tg (APPswe, PSEN1dE9) 85Dbo/Mmjax] mice were purchased from the Jackson Laboratory (Bar Harbor, USA; http://www.jax.org). The APP/PS1 transgenic founder lines were bred with C57BL/6J wild-type mice. The offspring were genotyped by PCR. Primer for genotyping were as follows: APP sense 5′-GACT GACCACTCGACCAGGTTCTG-3′, antisense 5′-CTTGTAAGTT GGATTCTCATATCCG-3′; and PS1 sense 5′-AATAGAGAACGGC AGGAGCA-3′, antisense 5′-GCCATGAGGGCACTAATCAT-3′.
Aβ preparation
Lyophilized, HPLC-purified Aβ 40 and Aβ 42 were synthesized by Pepmic Co., Ltd (Suzhou, China). Peptides were reconstituted in sterile water at a concentration of 400 μM and incubated at 37°C for 24 h to form aggregated Aβ which contains oliogomeric and fibrillar Aβ [16] .
Flow cytometric analysis
Aβ-treated MSCs were trypsinized and washed with phosphatebuffered saline (PBS), stained with PE-CD73 and PE-CD105 for 30 min at 4°C in the dark, and then washed twice with PBS and fixed in 500 μl of 1% paraformaldehyde. PE-conjugated isotypematched Abs were used as negative controls. Samples were analyzed on BD FACSCanto™ flow cytometer (BD Biosciences).
Cell viability assay
Cells were seeded in a 96-well flat-bottomed plate at a density of 2 × 10 4 cells/ml with 100 μl per well and incubated in media containing different concentrations Aβ40 or Aβ42 (0, 2, 5, and 10 μM) at 37°C for 3 days. Then, cells were treated with the 10 μl/well CCK8 solution for 1 h at 37°C and the absorbance was measured at 450 nm with a microplate reader.
Western blot analysis
Cells were lysed using lysis buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM PMSF, and a protease inhibitor cocktail from Roche Applied Science (Indianapolis, USA). After SDS-PAGE, the proteins were transferred onto a polyvinylidene difluoride membrane (Roche Molecular Biochemicals, Quebec, Canada), blocked with 5% non-fat milk in TBS-T buffer (20 mM Tris-HCl, pH 7.4, 137 mM NaCl, and 0.1% Tween-20) for 1 h at 37°C, and incubated overnight at 4°C with primary antibodies against the target proteins. After extensive wash, the membrane was incubated with the appropriate HRP-conjugated secondary antibody and then developed using the ECL System (Millipore, Billerica, USA).
Quantitative real-time PCR (qRT-PCR) analysis
Total RNA was extracted from cultured MSC using HP Total RNA kit (Omega, Norcross, USA). cDNA was synthesized using RevertAid First Strand cDNA Synthesis kit (Thermo, Rockford, USA). qRT-PCR was performed on Mastercycler pro sequence detection system (Eppendorf AG, Hamburg, Germany) using a FastStart Universal SYBR Green Master kit (Roche). Primer sequences are shown in Table 1 . Relative expression of α-SMA, PDGFRβ, or desmin was calculated by the delta-Ct (threshold cycle) of the target gene and normalized to that of GAPDH.
Immunofluorescences
Twelve-month-old APP/PS1 transgenic mice and matched littermates were anesthetized using 10% chloral hydrate and then sacrificed. After slow and constant cardiac perfusion with pre-cooled (4°C) normal saline and 4% paraformaldehyde, the bilateral cerebral hemispheres were collected and fixed in 4% paraformaldehyde for 24 h. The brain was then passed through a gradient of sterilized sucrose solutions (10%, 20%, and 30%) dehydrated, respectively, for 1 day, and frozened in OCT embedding medium (Leica, Wetzlar, Germany). A freezing microtome (Leica1950) was used to make a continuous series of 8-μm-thick frozen sections. The slides were then washed with PBS, blocked with 3% BSA for 1 h, and incubated with anti-CD31 and anti-desmin or anti-Aβ (6E10) and anti-α-SMA antibodies at 4°C overnight, and then with Alexa Fluor 488 and Alexa Fluor 555 secondary antibodies (Invitrogen, Carlsbad, USA) for 1 h at room temperature, mounted with DAPI Mounting Medium (Vector Laboratories, Burlingame, USA) and analyzed by using a Leica TCS SP5 Confocal microscope. 
Statistical analysis
Statistical analyses were performed using SPSS scientific software. Student's t-test was used for comparison of two groups and oneway ANOVA analysis was used for more than two comparisons. Differences with P values less than 0.05 were considered to be statistically significant.
Results
Loss of pericytes in APP/PS1 mice
To investigate the correlation between pericyte coverage and Aβ deposition on brain capillaries in APP/PS1 mice, the brain sections were first stained with antibodies against Aβs (6E10) and α-SMA (pericyte marker) by immunofluorescent staining in the cortex of 12-month-old mice. Genotype PCR results of APP/PS1 transgenic mice are shown in Supplementary Fig. S1 . Our results showed that Aβ level was increased by 8 folds in the cortex of APP/PS1 mice compared with littermate controls (Fig. 1A) . Surprisingly, pericytes coverage determined by desmin (pericyte marker) and CD31 (endothelial marker) co-staining were 40% lower in the cortex of APP/ PS1 mice than those in littermate groups (Fig. 1B) , indicating a negative correlation between levels of Aβs and pericyte coverage, i.e. the greater the levels of Aβs, the lesser the levels of pericyte coverage. These results further confirmed pericyte loss in AD.
Aβ inhibits the expressions of pericyte markers in MSCs
The perivascular pericytes in adult tissues are commonly recognized to arise from the recruitment and differentiation of mesenchymal progenitors during early development [17] . To determine whether accumulation of Aβs in brain is responsible for the loss of pericytes in human AD, we first determined whether Aβs are able to influence the transition of MSCs to pericytes. MSCs were incubated with various concentrations of Aβ 40 or Aβ 42 for 72 h, and then protein and mRNA expression levels of α-SMA, PDGFRβ and desmin were determined by western blot analysis and qRT-PCR. The results showed that the protein expression levels of α-SMA and desmin in Aβ 40 -treated cells were significantly reduced by 45% or 55%, respectively, as compared with those in the negative controls ( Fig. 2A) . Similar results were obtained in Aβ 42 -treated cells (Fig. 2B) . Furthermore, PCR analysis showed that in response to Aβ 40 or Aβ 42 treatment (Fig. 3) , the mRNA expression levels of α-SMA (Fig. 3A) , PDGFRβ (Fig. 3B) , and desmin (Fig. 3C) were 80%, 75%, or 60% lower than those in the control cells. In addition, FACS analysis showed that Aβs had no effect on the expression levels of MSC stem markers CD73 and CD105 ( Supplementary  Fig. S2 ). Aβs had no effect on cell viability as determined by CCK8 assay ( Supplementary Fig. S3 ). Taken together, these results indicated that Aβs could inhibit the expressions of pericyte markers but not the expressions of stem cell markers, in MSCs.
Inhibitory effects of Aβ on MSC-pericyte transition is Aβ-specific
To further determine whether the inhibitory effects of Aβ on MSCpericyte transition described above is Aβ-related specific, we examined the ability of 6E10, a mouse monoclonal antihuman Aβ protein antibody, to inhibit the Aβ-related effects on pericytes. It was found that Aβ 40 or Aβ 42 (5 μM)-treated MSCs markedly decreased the expressions of α-SMA and desmin at both protein level (Fig. 4A ) and mRNA level (Fig. 4B) . Anti-Aβ antibody 6E10 (1:100) nearly completely blocked this decrease, suggesting that pericyte differentiation induced by Aβs was indeed a direct effect on the MSCs (Fig. 4) . These results indicate that inhibitory effect of Aβ on MSCpericyte transition is Aβ-specific.
Aβ induces the activation of MAPK signal pathway
To explore the possible mechanism through which Aβs mediates MSC-pericyte transition, MSCs were stimulated by Aβ 40 or Aβ 42 for 10 min, and then the activation of signal pathway was detected by western blot analysis. Our results showed that Aβ can specifically active the ERK1/2 MAPK signal pathway (Fig. 5A) . Furthermore, cells were treated with 5 μM Aβs for 3 days in the presence or absence of PD98059 (20 μM), an MAPK inhibitor, and results showed that PD98059 blocked Aβ-induced inhibition in pericyte differentiation (Fig. 5B) . These results indicated that Aβ inhibits MSCpericyte transition through MAPK pathway.
Discussion
In this study, we focused on the effect of Aβ on the transition of mesenchymal precursor cells to pericytes. The present data demonstrated that accumulation of Aβ inhibits the differentiation of MSCs to pericytes through the MAPK pathway in culture.
Many independent studies have demonstrated that pericyte is degenerated and reduced in both the hippocampus and cortex in human AD [8, 11] . Mature pericytes are characterized by markers for desmin, PDGFRβ or α-SMA. Sagare et al. [8] reported that progression of pericytes is degenerated in APP sw/0 PDGFRβ +/− mice [8] .
Matthew et al. [11] reported that AD apolipoprotein E4 gene carriers developed accelerated pericyte degeneration and BBB breakdown compared with non-AD controls [11] . Consistent with the results of Sagare et al., our results showed that Aβ level was increased, whereas the vessels covered with desmin were lower, in APP/PS1 mice than those in littermate control groups, indicating a negative correlations between levels of Aβs and pericyte coverage, i.e. the greater the levels of Aβs, the lesser the levels of pericyte coverage (Fig. 1) . We speculate that the accumulation of Aβ in brain may cause pericytes loss. It is widely recognized that pericytes have mesenchymal origin [17] . MSCs have the potential to differentiate into many other cell types, including neuronal cells, myogenic cells, adipocytes, osteocytes, and perivascular cells in culture [18] . In order to determine whether the loss of pericytes was caused by an inhibitory effect of Aβ accumulation on pericyte differentiation, we measured the expression levels of pericytes marker (desmin, PDGFRβ, or α-SMA) after Aβ exposure to MSC culture medium. This hypothesis is strengthened by the fact that Schultz et al. [19] found that oligomeric Aβ42 could induce the shedding of neuronal glial antigen 2 (NG2), another pericyte marker. In the present study, we demonstrated that after 3 days of the pericyte differentiation culture, western blot analysis (Fig. 2) and the real-time PCR analysis (Fig. 3) both showed that the levels of desmin, PDGFRβ and α-SMA were all significantly decreased with exposure to various concentrations of Aβs, compared with those in the control group. In addition, 6E10, an anti-Aβ antibody [16] , could abolish the Aβ-induced inhibition of pericyte differentiation, supporting the suggestion that Aβ itself is the active agent.
MAPK signal has diverse biological functions in response to a broad spectrum of stimulations, such as growth cytokines, stress, TGF-β, and ceramides. The MAPK family members play a vital role in cell proliferation, differentiation, survival, and development by activating gene expression, mitosis, and metabolism. Jin et al. [16] have reported that Aβ induces neurogenesis via NPY, 5-HT2B, and dynamin, which is mediated by the activation of ERK1/2-directed signaling pathways. In this study, we found that ERK1/2 MAPK was overactivated after Aβ exposure, and in the presence of PD98059, a MAPK inhibitor, Aβ-induced inhibition in pericyte differentiation was blocked (Fig. 5) , indicating that Aβ inhibits MSCpericyte transition possibly through the MAPK pathway, which nevertheless needs to be verified in future studies.
In summary, we showed that brain pericyte loss might be triggered by the inhibitory effects of Aβ on the transition of MSCs to pericytes. Future studies should focus on whether pericyte rescue by promoting the differentiation of pericytes can slow down the Alzheimer-like neurodegeneration cascade, which may represent a novel therapeutic target to modify disease progression. Exploration of molecular cues that cause loss of pericytes in AD models and AD patients may ultimately lead to the discovery of new therapeutics to control pericyte loss and consequently slow down the pathogenic neurodegeneration cascade in AD.
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